Background {#Sec1}
==========

Health expenditure has risen for many years worldwide parallel with the demand for health care services \[[@CR1]\]. As a result, when making decisions on the use of limited health resources, policy makers need to consider not only the clinical benefits but also economic information, including value for money and the budget impact of particular health interventions and technologies \[[@CR2]\]. Even though cost is an important parameter for economic analysis, researchers often pay little attention to identifying accurate and reliable cost information compared to clinical parameters \[[@CR3]\]. In common with the production and delivery of technologies in many industries, the unit cost of health technologies and interventions is likely to be affected by scale due to the efficiency gained by an increased level of production. This results in a non-linear function of the cost of production of health services or health technologies in relation to the size of production. Despite this, a few economic evaluation studies have incorporated economies of scale in their analysis \[[@CR4]\]. The *WHO's Choosing Interventions that are Cost*-*Effective (CHOICE)* project recommends the application of economies and diseconomies of scale when estimating the costs and impacts of various interventions with different coverage levels \[[@CR5], [@CR6]\].

Further, the *Reference Case* developed by the International Decision Support Initiative (iDSI) underlines the need to apply economies of scale in cost estimation, where appropriate \[[@CR7]\]. Although incorporating economies of scale in an analysis is very reasonable, it is methodologically challenging, especially in low- and middle-income countries where health information infrastructures have not been well established. Thus, this study aims to investigate the feasibility and significance of applying the economies of scale concept to the economic evaluation and budget impact analysis of economic models for pneumococcal conjugate vaccines (PCV) and human papillomavirus (HPV) vaccine in the Philippines. The vaccine cases were selected for this study because of two reasons. First, it has been well recognised that the cost of the supply chain and vaccine procurement can be significantly affected by the number of vaccinations \[[@CR8]\]. Second, the Government of the Philippines set their milestone to increase budget allocation every year for expansion the newly introduced vaccines. Their main priorities are infants, children, women, and elderly persons nationwide \[[@CR9]\]. Strengthening the evidence on financial sustainability through the finding from this study can support decision making in the expanded program on immunization.

Methods {#Sec2}
=======

Model structures {#Sec3}
----------------

Two economic evaluation models used for previous economic evaluations of PCV and HPV in the Philippines were deployed in this study. Details of the models are described elsewhere in open-access journals \[[@CR10], [@CR11]\]. Briefly, the two models compared both the costs and outcome of the PCV and HPV vaccination with 0--1 years for both boys and girls, and 11 years and above for girls, respectively. The models compared the vaccination programmes with the current practices, i.e. do nothing in the case of PCV and cervical cancer screening (visual inspection with acetic acid---VIA) in the case of HPV. The lifetime time horizons with the discount rate of 3.5% for both costs and outcome in terms of quality-adjusted life years (QALYs) were used consistently across the two models. Because this study focuses on applying the economies of scale concept to costing estimations, the epidemiological intervention effectiveness and utility information have been unchanged.

Fixed costs {#Sec4}
-----------

Using the provider's perspective, the costs of the vaccination programmes were divided into two groups, i.e. fixed costs and variable costs. The fixed costs included cold chain-related infrastructure investment, which means that the costs of a functioning cold chain system were independent from the target population proportion to be covered by the vaccine programme. In other words, the higher the number of vaccinations provided was, the lower was the cold chain vaccination cost attached to each vaccine provided. The data on the cold chain investment in the Philippines were gathered from the Department of Health-Family Health Office, Ministry of Health (personal communication from programme manager of the Expanded Program on Immunization, the Philippines). Since the cold chain is used to support three different vaccination programmes, namely PCV, HPV, and inactivated polio vaccine, this joint cost was divided according to the number of vaccine dosages currently under the cold chain system. The PCV programme accounts for 55% of the total investment and the HPV programme accounts for 25%. The costs are presented in Table [1](#Tab1){ref-type="table"}.Table 1Estimating cold chain investment cost per annum in relation to each vaccination programmeType of vaccineNo. of dosesProportionInvestment in cold chain (USD per year)Pneumococcal conjugate vaccine6,600,0000.557790,000Human papillomavirus vaccine3,044,1000.257364,000Inactivated polio vaccine2,200,0000.186263,000Total11,844,1001.001,417,000

Variable costs {#Sec5}
--------------

The variable costs included vaccine acquisition costs, wastage costs, and logistic and administration costs. Originally, it was planned that the vaccine acquisition costs would be derived from a price survey among the vaccine companies. Despite requests directly from the Pharmaceutical Division of the Department of Health Philippines to vaccine companies, information about vaccine costs and administrative costs was not forthcoming. As such, the researchers used the current procurement prices for the scenario regarding the current vaccine coverage, i.e. 90, 88 and 86% for the first, second, and booster dose of PCV, respectively, the correspondence based on the 2013 coverage rates for the DPT-HepB-Hib vaccination for the first two doses and for the measles vaccination administered at the same time as the booster dose \[[@CR9]\], and 10% for the HPV vaccination programmes were assumed to correspond to the achieved 2012 incorporate rate of pharmacy administration services regarding the drug price reference index of the DOH \[[@CR12]\]. The researchers assumed the cheapest price for vaccine acquisition for 100% coverage of the HPV vaccine using the current GAVI's procurement prices (USD 10.30 for PCV10, USD 10.40 for PCV13, and USD 4.50 for HPV) \[[@CR13], [@CR14]\] and varied the prices between the current coverage and 100% coverage using a linear assumption. The vaccine wastage costs, and logistic and administration costs, were assumed to be at 25% of the vaccine acquisition costs according to the observed rates in Thailand \[[@CR15]\]. These cost parameters are showed in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2Cost of PCV vaccination (USD) for different percentages of vaccination coverage% vaccine coverageNo. of vaccinated childrenAverage fixed costAverage variable costsTotal cost of PCV vaccination per doseCost of cold chain per vaccinationPCV10PCV13PCV10PCV13Vaccine costLogistic and administration costWastage costVaccine costLogistic and administration costWastage cost10220,0001.2014.742.950.7416.543.310.8319.6321.8720440,0000.6014.252.850.7115.863.170.7918.4120.4230660,0000.4013.762.750.6915.183.040.7617.6019.3740880,0000.3013.262.650.6614.492.900.7216.8818.42501,100,0000.2412.772.550.6413.812.760.6916.2017.50601,320,0000.2012.282.460.6113.132.630.6615.5416.61701,540,0000.1711.782.360.5912.452.490.6214.9015.73801,760,0000.1511.292.260.5611.762.350.5914.2614.86901,980,0000.1310.792.160.5411.082.220.5513.6313.991002,200,0000.1210.302.060.5210.402.080.5212.9913.12Not taking into account economies of scale, the unit cost of PCV10 and PCV13 was USD 44.73 and USD 50.16*PCV* pneumococcal conjugate vaccine Table 3Cost of HPV vaccination (USD) for different percentages of vaccination coverage% vaccine coverageNo. of vaccinated girlsAverage fixed costAverage variable costsTotal cost of HPV vaccination per doseCost of cold chain per vaccinationVaccine costLogistic and administration costWastage cost10101,4701.215.13.00.82020202,9400.613.92.80.71830304,4100.412.82.60.61640405,8800.311.62.30.61550507,3500.210.42.10.51360608,8200.29.21.80.51270710,2900.28.01.60.41080811,7600.16.91.40.3990913,2300.15.71.10.371001,014,7000.14.50.90.26Not taking into account economies of scale, the unit cost per dose of HPV was USD 20*HPV* human papillomavirus vaccine

Incorporating economies of scale {#Sec6}
--------------------------------

For the cervical cancer modelling, the economies of scale were also applied to VIA screening and cryotherapy for the early stage of cervical cancer detected by the screening programme. The fixed costs included training and medical devices, e.g. cryotherapy units. The variable costs included labour costs and consumable materials such as acetic acid, CO~2~, etc. The data were collected from the MOH and are shown in Table [4](#Tab4){ref-type="table"}.Table 4Cost of cervical cancer screening (USD)% screening coverageNo. of eligible women per yearUnit cost of VIA screeningUnit cost of cryotherapyTotal cost of cervical cancer screening per woman10139,9412493320279,8821251830419,8241662340559,7651251850699,7061051460839,6471251870979,58810515801,119,53012518901,259,471115161001,399,41210514Not taking into account economies of scale, the unit cost of cervical cancer screening was USD 35.44*VIA* visual inspection with acetic acid

The treatment costs for pneumococcal infection, including its complications and cervical cancer for human papillomavirus infection, were collected in the Philippines and in Thailand when the data in the Philippines were not available. The details of these costs were available in previous publications \[[@CR10], [@CR11]\]. Because the treatment costs depend on general access to the health facilities for each individual, the researchers did not apply economies of scale in the costing estimation for the treatments.

Results {#Sec7}
=======

The results are presented in terms of an incremental cost-effectiveness ratio (ICER) for each vaccination programme with different coverage scenarios. Because there are many options for cervical cancer prevention and control, two comparators were represented in the analysis: (1) HPV vaccination plus cervical cancer screening compared with cervical cancer screening alone; and (2) HPV vaccination alone compared with cervical cancer screening alone. The first comparator is in line with the current policy option in the Philippines, whereas the second comparison was made to highlight the impact of economies of scale approach to economic evaluation when both policy choices were applicable for the approach. The economic analysis applied the ceiling threshold of Php 120,000 (USD 2835) in line with previous policy decisions for determining the value of health investment in the Philippines context. If the ICER was below the ceiling threshold, the intervention was considered to be cost-effective. If the ICER was lower than zero in this study, the intervention was considered to be a cost-saving option. In addition, the government budget implications for each policy option during the next 5 years are presented. All costs are presented in US dollars, USD, for the year 2012 (Php 0.024 = USD 1).

Table [5](#Tab5){ref-type="table"} shows a significant difference in the ICERs of PCV compared to the programme with no vaccination. Applying an economies of scale approach to estimating the cost of the vaccination programme accounted for a 62 and 71% reduction in ICERs for low vaccination coverage and up to 97 and 98% for high vaccination coverage in PCV10 and PCV13, respectively. It is noteworthy that the ICERs declined sharply with vaccination coverage equal to or above 80% as a result of herd protection. Nevertheless, the ICERs with an economies of scale approach did not change that policy conclusion---that PCV represents good value for money in the Philippine context.Table 5Incremental cost-effectiveness ratio of PCV vaccination compared to no vaccination% coveragePCV10 (USD/QALY)PCV13 (USD/QALY)Without taking into account EoS approachWith EoS approach% reduction of ICERWithout taking into account EoS approachWith EoS approach% reduction of ICER10^a^265510526219977607120^a^26559756519976977430^a^26559236719976507540^a^26558777019976097750^a^26558347219975697960^a^26557927319975308070^a^26557507519974918180^b^1439134971162319890^b^15331519712323898100^b^16141599712923898Herd protection was considered at a vaccination coverage rate of 80%*PCV* pneumococcal conjugate vaccine, *EoS* economies of scale, *ICER* incremental cost-effectiveness ratio^a^Low vaccination coverage^b^High vaccination coverage

Figure [1](#Fig1){ref-type="fig"} illustrates the budget implications of the PCV vaccination programmes, and the treatment of pneumococcal-related infections using and not using the economies of scale approach. The figure indicates that the 5-year budget impacts of the vaccination programmes using the economies of scale approach accounted for only 30 and 40% of the budget estimation without using the economies of scale approach for high (100%) and low (20%) vaccination coverage, respectively.Fig. 15-year budget impacts of PCV vaccination programmes with and without applying economies of scale. *PCV* pneumococcal conjugated vaccine, *EoS* economies of scale

Table [6](#Tab6){ref-type="table"} displays the ICERs of different coverage levels of the HPV vaccination programme on top of the cervical cancer screening compared to the different coverage of cervical cancer screening alone. The ICERs rely on coverage of cervical cancer screening---the lower the screening coverage was, the better was the value for the HPV vaccination programme given constant unit costs of vaccination and screening programmes (without taking into account economies of scale). These findings are contrary to the results represented in Table [7](#Tab7){ref-type="table"}, in which the economies of scale approach was applied to the costing estimation of both policy options, i.e. vaccine plus cervical cancer screening and cervical cancer screening alone. Most of the scenarios, especially with high vaccination coverage, suggest that the vaccination programme plus cervical cancer screening is a cost-saving option. At low coverage, the vaccination plus cervical cancer screening policy remains a cost-effective option.Table 6Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination and cervical cancer screening without taking into account economies of scaleICER (USD/QALY)Percent coverage of screening (not taking into account EoS approach)Percent coverage of HPV vaccine (not taking into account EoS approach)10203040506070809010010− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^20− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^30− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^40− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^50− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^60− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^70− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^80− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^90− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^100− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective Table 7Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination and cervical cancer screening with applying economies of scaleICER (USD/QALY)Percent coverage of screening (with EoS approach)Percent coverage of HPV vaccine (with EoS approach)10203040506070809010010− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^20− 470^a^− 330^a^− 190^a^− 50^a^100^b^250^b^400^b^560^b^720^b^880^b^30− 820^a^− 690^a^− 570^a^− 440^a^− 310^a^− 170^a^− 30^a^110^b^250^b^400^b^40− 1140^a^− 1040^a^− 920^a^− 810^a^− 690^a^− 570^a^− 450^a^− 320^a^− 190^a^− 60^a^50− 1460^a^− 1370^a^− 1270^a^− 1170^a^− 1060^a^− 960^a^− 850^a^− 730^a^− 620^a^− 500^a^60− 1780^a^− 1700^a^− 1610^a^− 1520^a^− 1430^a^− 1340^a^− 1240^a^− 1140^a^− 1050^a^− 940^a^70− 2090^a^− 2020^a^− 1950^a^− 1870^a^− 1800^a^− 1720^a^− 1640^a^− 1550^a^− 1470^a^− 1380^a^80− 2410^a^− 2350^a^− 2290^a^− 2220^a^− 2160^a^− 2090^a^− 2030^a^− 1960^a^− 1890^a^− 1810^a^90− 2720^a^− 2670^a^− 2620^a^− 2570^a^− 2520^a^− 2470^a^− 2420^a^− 2360^a^− 2300^a^− 2250^a^100− 3030^a^− 2990^a^− 2960^a^− 2920^a^− 2880^a^− 2840^a^− 2800^a^− 2760^a^− 2720^a^− 2680^a^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective

Table [8](#Tab8){ref-type="table"} presents the ICERs for the vaccination programme plus cervical cancer screening using the economies of scale approach compared to the screening programme without taking into account the economies of scale approach. It suggests similar findings to Table [7](#Tab7){ref-type="table"}.Table 8Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination with applying economies of scale and cervical cancer screening without taking into account economies of scaleICER (USD/QALY)Percent coverage of screening (not taking into account EoS approach)Percent coverage of HPV vaccine (with EoS approach)10203040506070809010010− 30^a^120^b^270^b^440^b^600^b^770^b^940^b^1120^b^1300^b^1480^b^20− 470^a^− 330^a^− 190^a^− 50^a^100^b^250^b^400^b^560^b^720^b^880^b^30− 820^a^− 690^a^− 570^a^− 440^a^− 310^a^− 170^a^− 40^a^110^b^250^b^400^b^40− 1140^a^− 1040^a^− 920^a^− 810^a^− 690^a^− 570^a^− 450^a^− 320^a^− 190^a^− 60^a^50− 1460^a^− 1370^a^− 1270^a^− 1170^a^− 1060^a^− 960^a^− 850^a^− 740^a^− 620^a^− 510^a^60− 1780^a^− 1700^a^− 1610^a^− 1520^a^− 1430^a^− 1340^a^− 1240^a^− 1150^a^− 1050^a^− 950^a^70− 2090^a^− 2020^a^− 1950^a^− 1870^a^− 1800^a^− 1720^a^− 1640^a^− 1550^a^− 1470^a^− 1380^a^80− 2410^a^− 2350^a^− 2290^a^− 2220^a^− 2160^a^− 2100^a^− 2030^a^− 1960^a^− 1890^a^− 1820^a^90− 2720^a^− 2670^a^− 2620^a^− 2570^a^− 2520^a^− 2470^a^− 2420^a^− 2360^a^− 2310^a^− 2250^a^100− 3030^a^− 2990^a^− 2960^a^− 2920^a^− 2880^a^− 2850^a^− 2810^a^− 2770^a^− 2720^a^− 2680^a^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective

Table [9](#Tab9){ref-type="table"} provides different findings---that without taking into account the economies of scale approach for the vaccination programme plus cervical cancer screening but with only the cervical cancer screening programme, the HPV vaccination plus cervical cancer screening policy was cost-ineffective in the Philippines except at 10% coverage for the screening programme. The higher the screening coverage was, the worse was the value for money of the vaccination programme and this indicated that the screening programme is a better choice for the Philippines.Table 9Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination without taking into account economies of scale and cervical cancer screening with applying economies of scaleICER (USD/QALY)Percent coverage of screening (with EoS approach)Percent coverage of HPV vaccine (not taking into account EoS approach)10203040506070809010010− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^20− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^30− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^40− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^50− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^60− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^70− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^80− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^90− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^100− 30^a^120^b^280^b^440^b^600^b^770^b^950^b^1120^b^1300^b^1480^b^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective

Figure [2](#Fig2){ref-type="fig"} displays the budget impact of the HPV vaccination programme plus cervical cancer screening with and without taking into account the economies of scale approach. This indicates that in applying the economies of scale approach for economic evaluation, the 5-year budget impacts were 40 and 93% of the estimation without applying economies of scale at high (100%) and low (20%) vaccination plus screening coverage, respectively.Fig. 25-year budget impacts of HPV vaccination programmes with and without applying economies of scale. *HPV* human papillomavirus vaccine, *EoS* economies of scale

Tables [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"}, [12](#Tab12){ref-type="table"}, and [13](#Tab13){ref-type="table"} illustrate the impact of economies of scale in terms of ICERs when comparing the HPV vaccination programme alone with the cervical cancer screening alone. They show a higher impact of the economies of scale approach compared to Tables [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, and [9](#Tab9){ref-type="table"}, resulting in preferable conclusion toward cervical cancer screening, particularly when high coverage of cervical cancer screening is compared to low coverage of HPV vaccination.Table 10Incremental cost-effectiveness ratio of HPV vaccination alone compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination and cervical cancer screening without taking into account economies of scaleICER (USD/QALY)Percent coverage of screening (not taking into account EoS approach)Percent coverage of HPV vaccine (not taking into account EoS approach)% coverage102030405060708090100101860^b^− 11100^a^− 3480^a^− 2540^a^− 2140^a^− 1890^a^− 1720^a^− 1580^a^− 1450^a^− 1340^a^20410^b^1670^b^6730^c^− 15430^a^− 5080^a^− 3420^a^− 2700^a^− 2280^a^− 1990^a^− 1770^a^30170^b^670^b^1510^b^3230^c^9470^c^− 30430^a^− 7260^a^− 4470^a^− 3330^a^− 2690^a^4060^b^370^b^780^b^1350^b^2250^b^3940^c^8580^c^114020^c^− 12250^a^− 6170^a^5010^b^230^b^490^b^810^b^1210^b^1750^b^2520^b^3800^c^6410^c^15380^c^60− 30^a^140^b^330^b^550^b^790^b^1080^b^1420^b^1850^b^2410^b^3200^c^70− 50^a^90^b^240^b^400^b^570^b^750^b^950^b^1180^b^1430^b^1720^b^80− 70^a^50^b^170^b^300^b^430^b^560^b^700^b^840^b^990^b^1140^b^90− 80^a^20^b^120^b^230^b^330^b^430^b^540^b^640^b^740^b^830^b^100− 90^a^0^b^90^b^170^b^260^b^340^b^430^b^500^b^570^b^640^b^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective^c^Highly cost-ineffective Table 11Incremental cost-effectiveness ratio of HPV vaccination alone compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination and cervical cancer screening with applying economies of scaleICER (USD/QALY)Percent coverage of screening (with EoS approach)Percent coverage of HPV vaccine (with EoS approach)% coverage10203040506070809010010− 310^a^− 11450^a^− 2230^a^− 2620^a^− 2760^a^− 1960^a^− 2150^a^− 1640^a^− 1790^a^− 1910^a^20− 810^a^760^b^1530^b^− 11420^a^− 5400^a^− 2810^a^− 2870^a^− 1960^a^− 2130^a^− 2230^a^30− 1140^a^− 520^a^− 840^a^590^b^5880^c^− 12850^a^− 5170^a^− 2330^a^− 2510^a^− 2600^a^40− 1450^a^− 1110^a^− 1420^a^− 940^a^− 160^a^− 750^a^1480^b^1350^b^− 3400^a^− 3150^a^50− 1750^a^− 1540^a^− 1840^a^− 1600^a^− 1290^a^− 1830^a^− 1470^a^− 2640^a^− 2450^a^− 1840^a^60− 2050^a^− 1920^a^− 2190^a^− 2070^a^− 1910^a^− 2370^a^− 2250^a^− 3010^a^− 3020^a^− 3050^a^70− 2350^a^− 2270^a^− 2530^a^− 2460^a^− 2390^a^− 2780^a^− 2750^a^− 3320^a^− 3380^a^− 3450^a^80− 2650^a^− 2610^a^− 2850^a^− 2820^a^− 2800^a^− 3150^a^− 3160^a^− 3630^a^− 3700^a^− 3790^a^90− 2950^a^− 2930^a^− 3160^a^− 3170^a^− 3170^a^− 3490^a^− 3530^a^− 3930^a^− 4020^a^− 4110^a^100− 3250^a^− 3250^a^− 3470^a^− 3500^a^− 3520^a^− 3820^a^− 3870^a^− 4230^a^− 4320^a^− 4420^a^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective^c^Highly cost-ineffective Table 12Incremental cost-effectiveness ratio of HPV vaccination alone compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination with applying economies of scale and cervical cancer screening without taking into account economies of scaleICER (USD/QALY)Percent coverage of screening (not taking into account EoS approach)Percent coverage of HPV vaccine (with EoS approach)% coverage102030405060708090100101860^b^− 11100^a^− 3480^a^− 2540^a^− 2140^a^− 1890^a^− 1720^a^− 1580^a^− 1450^a^− 1340^a^20− 170^a^700^b^4160^c^− 10880^a^− 3830^a^− 2680^a^− 2170^a^− 1860^a^− 1640^a^− 1470^a^30− 770^a^− 540^a^− 200^a^470^b^2770^b^− 11610^a^− 3190^a^− 2130^a^− 1670^a^− 1380^a^40− 1190^a^− 1120^a^− 1060^a^− 1000^a^− 950^a^− 920^a^− 970^a^− 4110^a^− 160^a^− 260^a^50− 1550^a^− 1550^a^− 1580^a^− 1630^a^− 1740^a^− 1910^a^− 2230^a^− 2840^a^− 4220^a^− 9370^a^60− 1890^a^− 1930^a^− 2000^a^− 2090^a^− 2230^a^− 2420^a^− 2700^a^− 3100^a^− 3710^a^− 4680^a^70− 2210^a^− 2280^a^− 2370^a^− 2480^a^− 2630^a^− 2820^a^− 3070^a^− 3390^a^− 3810^a^− 4370^a^80− 2530^a^− 2610^a^− 2720^a^− 2840^a^− 2990^a^− 3180^a^− 3400^a^− 3680^a^− 4020^a^− 4430^a^90− 2840^a^− 2940^a^− 3050^a^− 3180^a^− 3330^a^− 3520^a^− 3730^a^− 3970^a^− 4260^a^− 4600^a^100− 3150^a^− 3250^a^− 3370^a^− 3510^a^− 3660^a^− 3840^a^− 4040^a^− 4270^a^− 4530^a^− 4820^a^*ICER* incremental cost-effectiveness ratio, *EoS* economies of scale, *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective^c^Highly cost-ineffective Table 13Incremental cost-effectiveness ratio of HPV vaccination alone compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination without taking into account economies of scale and cervical cancer screening with applying economies of scaleICER (USD/QALY)Percent coverage of screening (with EoS approach)Percent coverage of HPV vaccine (not taking into account EoS approach)% coverage10203040506070809010010− 310^a^− 11450^a^− 2230^a^− 2620^a^− 2760^a^− 1960^a^− 2150^a^− 1640^a^− 1790^a^− 1910^a^20− 220^a^1730^b^4100^c^− 15970^a^− 6660^a^− 3550^a^− 3410^a^− 2380^a^− 2480^a^− 2540^a^30− 200^a^700^b^860^b^3350^c^12580^c^− 31670^a^− 9250^a^− 4670^a^− 4180^a^− 3910^a^40− 200^a^390^b^410^b^1410^b^3030^c^4100^c^11030^c^119470^c^− 15490^a^− 9070^a^50− 190^a^240^b^230^b^840^b^1660^b^1820^b^3280^c^3990^c^8180^c^22910^c^60− 190^a^150^b^140^b^570^b^1110^b^1130^b^1870^b^1940^b^3100^c^4840^c^70− 190^a^100^b^80^b^420^b^810^b^790^b^1270^b^1240^b^1860^b^2630^b^80− 190^a^60^b^40^b^310^b^620^b^590^b^940^b^890^b^1300^b^1780^b^90− 190^a^30^b^10^b^240^b^500^b^460^b^740^b^680^b^980^b^1320^b^100− 190^a^0^b^− 20^b^190^b^400^b^370^b^600^b^530^b^780^b^1030^b^*ICER* incremental cost-effectiveness ratio; *EoS* economies of scale; *HPV* human papillomavirus vaccine^a^Cost-effective^b^Cost-ineffective^c^Highly cost-ineffective

Discussion {#Sec8}
==========

The concept of economies of scale indicates that production and delivery unit costs diminish at greater scales of production \[[@CR16], [@CR17]\]. This study demonstrates the importance of using an economies of scale methodological approach in estimating the costs for the economic evaluations and budget impact analyses of the two vaccination programmes. This study assumes that economies of scale for vaccine unit costs yield different ICERs and budget impact estimations compared to conventional costing estimation in economic modelling, which assume constant average programme costs across different levels of service utilization. The new methodological approach may lead to different conclusions from the initial analysis undertaken and in this instance could contribute to alternative policy decisions regarding the adoption and roll-out of the PCV and HPV vaccines in the national vaccination programme in the Philippines. As a result, we believe that using economies of scale in costing estimation for economic evaluations and budget impact analyses is an appropriate approach and better categorises the nature of the problems regarding the decisions that policy makers face in the Philippines.

This is very important, especially in counties that are currently responsible for paying for the vaccine in their vaccination programmes or graduating from GAVI alliance. Further, it demonstrates the substantial impact on vaccine utilisation that GAVI-negotiated pricing could have in countries that do not receive direct GAVI support. Thus, it is in the interest of GAVI and other institutions at national and international levels concerned with improving access to vaccination to increase active support for advancing analytical methods that incorporate economies of scale in economic evaluation and budget impact analysis. These methodological advancements would also better inform National Immunization Technical Advisory Groups (NITAGs) and relevant public health authorities regarding the value for money and budget implications of the vaccine investment. Moreover, this approach is likely to be generalizable to the analysis of other types of technology and interventions beyond the vaccine programme area.

A key finding of this study is that incorporating economies of scale in the cost estimation in economic evaluation yielded higher magnitude of the value for health, especially with high vaccination coverage, in comparison without taking into account economies of scale. Our findings are in line with a systematic review of malaria control intervention conducted by White et al. \[[@CR18]\]. The review indicated the effect of the scale of study on estimates of costs based on the number of beneficiaries or patients and concluded that economies of scale may result in cost savings per unit when an intervention is widely implemented. Our study adds to the very limited evidence about the relationship and impact of cost and scale of health interventions in terms of determining resource allocation, especially in resource-limited settings. We are aware that our results should be replicated to draw more concrete conclusions. Yet, resent research showed there is a higher tendency to find a positive result due to taking economies of scale than diseconomies and constant economies of scale \[[@CR19]\]. However, results still vary across the wide range of settings and the selected outputs. Further studies may apply more accurate data in order to contribute to more productive output for the concept of incorporating economies of scale in cost estimation.

This study has some limitations, mainly related to assumptions required, due to incomplete information on how costs change in relation to volume. In particular, the relationship between the unit cost of vaccine at different levels of vaccine coverage has been approximated using a linear relationship where increasing coverage results in proportionate price reductions. Diseconomies of scale (where the unit cost actually increases with increasing volume) \[[@CR20]\] have not been considered in this analysis. Although unit prices for vaccines are unlikely to be affected by diseconomies of scale, geographical and administrative issues may cause some diseconomies, particularly where near universal vaccine coverage is attempted. Second, this study only adopts the government perspective and ignores direct non-medical costs and indirect costs. However, many indirect costs, such as patient travel costs to access health facilities, would be borne on a per patient basis and would be unlikely to change with the number of patients reached by a national programme.

Conclusions {#Sec9}
===========

This analysis has highlighted the need for more research into the production cost function of vaccination programmes and related health services in order to more accurately capture costs at scale, ultimately facilitating better-informed decisions about access to health technologies and interventions.

ICERs

:   incremental cost-effectiveness ratios

CHOICE

:   WHO's Choosing Interventions that are Cost-Effective project

iDSI

:   International Decision Support Initiative

PCV

:   pneumococcal conjugate vaccine

HPV

:   human papillomavirus vaccine

VIA

:   visual inspection with acetic acid

QALYs

:   quality-adjusted life years

USD

:   US dollars

DPT-HepB-Hib

:   Diphtheria, Tetanus, Pertussis, Hepatitis B recombinant and Haemophilus influenza type B combined vaccine

DOH

:   Department of Health

GAVI

:   Global Alliance for Vaccines and Immunization

CO~2~

:   carbon dioxide

MOH

:   Ministry of Health

EoS

:   economies of scale

NITAGs

:   National Immunization Technical Advisory Groups
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